Cambrian's anti-aging mission expands with new fibrotic disease biotech
Cambrian BioPharma has a new pipeline company focused on a disease target that hasn’t met much success.
The new drug developer, called Isterian Biotech, emerged from stealth Thursday morning, Cambrian announced. Georg Terstappen, Cambrian’s EVP of drug discovery, will be Isterian’s president and board chair.
Cambrian CEO James Peyer tells Endpoints News the biotech is focused on developing inhibitor molecules for transglutaminase 2, also called TG2.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.